7697-28-1Relevant articles and documents
ORGANIC COMPOUNDS
-
Page/Page column 53-54, (2011/04/14)
The present invention provides compounds of the following structure; [in-line-formulae]A-L1-B-C-D[/in-line-formulae] that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.
FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA
-
Page/Page column 54, (2010/11/30)
Compounds of formula (1): are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitor of tumor necrosis factor-alpha (TNF- ) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF- activity, in particular inflammations.
The first regioselective metalation and functionalization of unprotected 4-halobenzoic acids
Gohier, Frederic,Castanet, Anne-Sophie,Mortier, Jacques
, p. 1501 - 1504 (2007/10/03)
(Chemical Equation Presented) By treatment with s-BuLi, s-BuLi/TMEDA, or t-BuLi at ~-78°C, 4-fluoro- and 4-chlorobenzoic acids (1a,b) are metalated preferentially in the position adjacent to the carboxylate. A complete reversal in regioselectivity is observed for 1a when treated with LTMP; a sequential process involving a rapid intraaggregate lithiation through a quasi dianion complex "QUADAC" is postulated to explain the unusual reactivity of Me2S2 and I2.